Amendments to the Specification

Please replace paragraphs [0055], [0057] and [0073] with the following paragraphs:

[0055] The peptide sequence that contains intended peptide cleavage points relevant for the target enzyme can also be constructed such that the intended peptide cleavage point is repeated a plurality of times, for example by:

-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln-Gly-Pro-Leu-Gly--Ile-Ala-Gly-Gln **SEQ ID No. 6**

or

-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys-Phe-Lys- **SEQ. ID No. 7**

or a repetitive peptide sequence can be integrated that increases the distance between the thiol-binding group and the relevant intended peptide cleavage point, as for example by:

$-(Gly)_n$-Phe-Lys-Phe-Lys- **SEQ ID No. 8 and 10-27**

with, preferably, n = 2 to 20, more preferably $n \leq 12$.

[0057] Drugs or drug derivatives, containing a cytokine, of the conjugate according to the invention can be prepared





for example, by reacting the cytokine with a space molecule containing a thiol-binding group, which space molecule exhibits a carboxylic acid or and activated carboxylic acid.

[0073] Fig. 2 shows HPLC chromatograms (gel chromatography, Biosil 250 SEC column, Biorad) of a conjugate according to the invention (HSA-Cys^{34}-2), which is cleavable by the matrix metalloprotease MMP 9. The absorption at 495 nm is also plotted versus the retention time in min. (A) Chromatogram of the conjugate HSA-Cys^{34}-2 before incubation with MMP 9 (t = 0). (B) Chromatogram of the conjugate HSA-Cys^{34}-2 after incubation with MMP 9 for 30 min (t = 30 min)and also showing a peak for fragment DOXO-Gln-Gly-Ala-Ile residues 1-4 of **SEQ ID No. 9**.